A dose- and time-controllable syngeneic animal model of breast cancer microcalcification

Breast Cancer Research and Treatment

Volumn 122, Issue 1, 2010, Pages 87-94

  Liu, Fangbing ^a   Misra, Preeti ^a   Lunsford, Elaine P ^a   Vannah, Joanne T ^a   Liu, Yuxia ^a   Lenkinski, Robert E ^a   Frangioni, John V ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Animal models; BMP 2; Breast cancer; Micro CT; Micro SPECT CT; Microcalcifications

Indexed keywords

ALKALINE PHOSPHATASE; COMPLEMENTARY DNA; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TECHNETIUM 99M; BMP2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT PROTEIN; TECHNETIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CALCIFICATION; BREAST CANCER; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MODEL; DRUG HALF LIFE; ENZYME ASSAY; ESCHERICHIA COLI; FISCHER 344 RAT; ISOTOPE LABELING; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PALPATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME; ANIMAL; CALCINOSIS; CANCER TRANSPLANTATION; CHEMICALLY INDUCED; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DOSE RESPONSE; DRUG SCREENING; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENETICS; HALF LIFE TIME; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; ISOGRAFT; METABOLIC CLEARANCE RATE; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION; TOXICITY;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CALCINOSIS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAPERITONEAL; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLIC CLEARANCE RATE; NEOPLASM TRANSPLANTATION; PROTEIN FOLDING; RATS; RATS, INBRED F344; RECOMBINANT PROTEINS; TECHNETIUM; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, ISOGENEIC;

EID: 77953545483     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0535-6     Document Type: Article

References (31)

1. SA Feig EA Sickles WP Evans MN Linver 2004 Re: changes in breast cancer detection and mammography recall rates after the introduction of a computer-aided detection system J Natl Cancer Inst 96 1260 1261 15316065 author reply 1261
2. MP Morgan MM Cooke GM McCarthy 2005 Microcalcifications associated with breast cancer: an epiphenomenon or biologically significant feature of selected tumors? J Mammary Gland Biol Neoplasia 10 181 187 10.1007/s10911-005-5400-6 16025224 (Pubitemid 41031007)
3. PC Stomper J Geradts SB Edge EG Levine 2003 Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass AJR Am J Roentgenol 181 1679 1684 14627596
4. L Liberman 2004 Breast cancer screening with MRI-what are the data for patients at high risk? N Engl J Med 351 497 500 10.1056/NEJMe048117 1:CAS:528:DC%2BD2cXmtFaktLs%3D 15282358 (Pubitemid 38988600)
5. WA Berg IN Weinberg D Narayanan ME Lobrano E Ross L Amodei L Tafra LP Adler J Uddo W Stein 3rd, et al. 2006 High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer Breast J 12 309 323 10.1111/j.1075-122X.2006.00269.x 16848840 (Pubitemid 43989975)
6. RR Raylman S Majewski MF Smith J Proffitt W Hammond A Srinivasan J McKisson V Popov A Weisenberger CO Judy, et al. 2008 The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements Phys Med Biol 53 637 653 10.1088/0031-9155/53/3/009 18199907 (Pubitemid 351496210)
7. X Wu H Xiao 2009 Progress in the detection of human genome structural variations Sci China C Life Sci 52 560 567 10.1007/s11427-009-0078-4 1:CAS:528:DC%2BD1MXnvVWls7g%3D 19557334
8. C Ferranti G Coopmans de Yoldi E Biganzoli S Bergonzi L Mariani G Scaperrotta M Marchesini 2000 Relationships between age, mammographic features and pathological tumour characteristics in non-palpable breast cancer Br J Radiol 73 698 705 1:STN:280:DC%2BD3M%2Fjs1OntQ%3D%3D 11089459
9. AJ Evans E Kutt C Record M Waller L Bobrow S Moss 2007 Radiological and pathological findings of interval cancers in a multi-centre, randomized, controlled trial of mammographic screening in women from age 40-41 years Clin Radiol 62 348 352 10.1016/j.crad.2006.10.010 1:STN:280:DC%2BD2s7jt1entQ%3D%3D 17331828
10. KR Bhushan P Misra F Liu S Mathur RE Lenkinski JV Frangioni 2008 Detection of breast cancer microcalcifications using a dual-modality SPECT/NIR fluorescent probe J Am Chem Soc 130 17648 17649 10.1021/ja807099s 1:CAS:528:DC%2BD1cXhsVKlu7rL 19055348
11. KR Bhushan E Tanaka JV Frangioni 2007 Synthesis of conjugatable bisphosphonates for molecular imaging of large animals Angew Chem Int Ed Engl 46 7969 7971 10.1002/anie.200701216 1:CAS:528:DC%2BD2sXht1Kit7fI 17868163 (Pubitemid 350033468)
12. RE Lenkinski M Ahmed A Zaheer JV Frangioni SN Goldberg 2003 Near-infrared fluorescence imaging of microcalcification in an animal model of breast cancer Acad Radiol 10 1159 1164 10.1016/S1076-6332(03)00253-8 14587634 (Pubitemid 37266307)
13. A Zaheer RE Lenkinski A Mahmood AG Jones LC Cantley JV Frangioni 2001 In vivo near-infrared fluorescence imaging of osteoblastic activity Nat Biotechnol 19 1148 1154 10.1038/nbt1201-1148 1:CAS:528:DC%2BD3MXptV2rtL4%3D 11731784 (Pubitemid 33115701)
14. AS Haka KE Shafer-Peltier M Fitzmaurice J Crowe RR Dasari MS Feld 2002 Identifying microcalcifications in benign and malignant breast lesions by probing differences in their chemical composition using Raman spectroscopy Cancer Res 62 5375 5380 1:CAS:528:DC%2BD38Xnt1yntro%3D 12235010
15. F Liu N Bloch KR Bhushan AM De Grand E Tanaka S Solazzo PM Mertyna N Goldberg JV Frangioni RE Lenkinski 2008 Humoral bone morphogenetic protein 2 is sufficient for inducing breast cancer microcalcification Mol Imaging 7 175 186 1:CAS:528:DC%2BD1MXhsleltw%3D%3D 19123988
16. JM Wozney V Rosen AJ Celeste LM Mitsock MJ Whitters RW Kriz RM Hewick EA Wang 1988 Novel regulators of bone formation: molecular clones and activities Science 242 1528 1534 10.1126/science.3201241 1:CAS:528:DyaL1MXkvFantr8%3D 3201241
17. LF Vallejo M Brokelmann S Marten S Trappe J Cabrera-Crespo A Hoffmann G Gross HA Weich U Rinas 2002 Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli J Biotechnol 94 185 194 10.1016/S0168-1656(01) 00425-4 1:CAS:528:DC%2BD38XktFSqsA%3D%3D 11796171 (Pubitemid 34127660)
18. T Katagiri A Yamaguchi M Komaki E Abe N Takahashi T Ikeda V Rosen JM Wozney A Fujisawa-Sehara T Suda 1994 Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage J Cell Biol 127 1755 1766 10.1083/jcb.127.6.1755 1:CAS:528:DyaK2cXmvFemtLs%3D 7798324 (Pubitemid 24380911)
19. 99mTc preloading strategy J Nucl Med 48 1379 1389 10.2967/jnumed.107.040303 1:CAS:528:DC%2BD2sXhtVSktb3O 17631555 (Pubitemid 47242804)
20. Thompson SW, Hunt RD (1996) Selected histochemical and histopathological methods. Charles C. Thomas, Springfield
21. A Zaheer M Murshed AM De Grand TG Morgan G Karsenty JV Frangioni 2006 Optical imaging of hydroxyapatite in the calcified vasculature of transgenic animals Arterioscler Thromb Vasc Biol 26 1132 1136 10.1161/01.ATV.0000210016. 89991.2a 1:CAS:528:DC%2BD28XjsVersrY%3D 16484598 (Pubitemid 43732123)
22. P Knaus W Sebald 2001 Cooperativity of binding epitopes and receptor chains in the BMP/TGFbeta superfamily Biol Chem 382 1189 1195 10.1515/BC.2001.149 1:CAS:528:DC%2BD3MXnslGlt7s%3D 11592400 (Pubitemid 32894025)
23. S Long L Truong K Bennett A Phillips F Wong-Staal H Ma 2006 Expression, purification, and renaturation of bone morphogenetic protein-2 from Escherichia coli Protein Expr Purif 46 374 378 10.1016/j.pep.2005.09.025 1:CAS:528:DC%2BD28XjtFOlur4%3D 16298141
24. S Steinert TC Kroll I Taubert L Pusch P Hortschansky K Hoffken S Wolfl JH Clement 2008 Differential expression of cancer-related genes by single and permanent exposure to bone morphogenetic protein 2 J Cancer Res Clin Oncol 134 1237 1245 10.1007/s00432-008-0396-0 1:CAS:528:DC%2BD1cXht1anu7%2FL 18446370
25. EL Alarmo T Kuukasjarvi R Karhu A Kallioniemi 2007 A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7 Breast Cancer Res Treat 103 239 246 10.1007/s10549-006-9362-1 1:CAS:528:DC%2BD2sXltlaqtrs%3D 17004110 (Pubitemid 46789146)
26. JR Dimar 2nd SD Glassman JK Burkus PW Pryor JW Hardacker LY Carreon 2009 Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis J Bone Joint Surg Am 91 1377 1386 10.2106/JBJS.H.00200 19487515
27. JH Clement M Raida J Sanger R Bicknell J Liu A Naumann A Geyer A Waldau P Hortschansky A Schmidt, et al. 2005 Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells Int J Oncol 27 401 407 1:CAS:528:DC%2BD2MXnsl2rtLc%3D 16010421
28. Y Katsuno A Hanyu H Kanda Y Ishikawa F Akiyama T Iwase E Ogata S Ehata K Miyazono T Imamura 2008 Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway Oncogene 27 6322 6333 10.1038/onc.2008.232 1:CAS:528:DC%2BD1cXht1Ont7fM 18663362
29. EM Langenfeld SE Calvano F Abou-Nukta SF Lowry P Amenta J Langenfeld 2003 The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells Carcinogenesis 24 1445 1454 10.1093/carcin/bgg100 1:CAS:528:DC%2BD3sXnt1Kjsr0%3D 12819188 (Pubitemid 37160834)
30. EM Langenfeld J Langenfeld 2004 Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors Mol Cancer Res 2 141 149 1:CAS:528: DC%2BD2cXjtFWksbw%3D 15037653
31. C Scheufler W Sebald M Hulsmeyer 1999 Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution J Mol Biol 287 103 115 10.1006/jmbi.1999.2590 1:CAS:528:DyaK1MXhs1Ols70%3D 10074410 (Pubitemid 29134800)